Novo Nordisk Shares Plunge on Insulin's FDA Failure
Feb. 11 (Bloomberg) -- Bloomberg's Caroline Hyde reports that Novo Nordisk shares have fallen the most in a decade as the company's new insulin drug Tresiba has failed to win FDA approval in the United States. She speaks on Bloomberg Television's "The Pulse."
Most Recent Videos
Traders Bet on Brazil Despite Turmoil
41:24 - Bloomberg's Scarlet Fu and Joe Weisenthal take a look at two charts that show how traders are betting on Brazil. They speak on "What'd You Miss?" (Source: Bloomberg)